洞见 （ DJ00123987 ） —— 不一样的观点，不一样的故事， 3000 万人订阅的微信大号。点击标题下 蓝字 " 洞见 " 关注，我们将为您提供有价值、有意思的延伸阅读。 作者： 洞见Moon 层次不同，沟通的语言也不同。 ♬ 点上方播放按钮可收听 洞见主播安东尼朗读音频 卡耐基年轻时，参加过一场慈善晚宴。 宴会宾客如云，各行各业的人三五成群，忙着高谈阔论。 卡耐基却没有着急参与其中，而是暗暗打听宾客的背景。 摸清每个人的情况后，卡耐基才走近人群开始攀谈。 面对普通民众，他就用自己的糟糕经历引起共情； 面对职场精英，他就和他们聊金融、经济走势； 面对政府要员，他就和他们探讨政策、社会。 一场宴会下来，无论权贵还是普通人，都觉得与他交谈如沐春风。 卡耐基把这段经历写进自传，还说： 成功的人际关系在于，捕捉对方的需求，而非表达自己的 需求。 说白了就是：见什么人，说什么话。 和底层人用情绪说话 底层社会的运行法则，是情绪而非理性。 为什么奶头乐、短剧爽片在底层更盛行？ 因为它们提供的是即时情绪反馈，而非复杂思考。 为什么罔顾事实，非黑即白的极端言论在底层更有市场？ 因为情绪化的解释比复杂的现实更容易接受 ...

6月24日，观察者网查询苹果公司官网发现，苹果国补页面注释更新为："国补仅限 Apple Store 在线商 店（北京收货地址）及零售店（上海）。在线商店还可享24个月免息分期"。指定产品享国家补贴，至 高省2000元。 限定的产品型号为：iPhone 16、iPhone 16e、iPhone 15 和 iPhone 15 Plus，iPad Air、iPad、iPad mini， 多款Apple Watch Series 10和Apple Watch SE，MacBook Air、MacBook Pro、iMac (仅限蓝色、粉色、绿 色和银色机型)、Mac miniMac Studio。 此前，苹果因 "官方渠道不参与国补" 的策略，导致部分用户转向了第三方平台。此次苹果官方接入国 补，让消费者在官方渠道直接享受"国补+官方服务"双重保障，打破此前仅第三方平台支持补贴的局 限。 电商平台在国补之外，往往还可搭配优惠券等购买，部分机型优惠超过了2000元，相较苹果官方渠道更 具价格优势。 目前，Apple 产品京东自营旗舰店显示："可享国家补贴地区"包括：吉林（吉林市）、安徽（亳州 市）、山东、浙江（宁波市 ...

明敏 发自 凹非寺 量子位 | 公众号 Qbitai 才官宣1个月，奥特曼未出世的AI硬件，已陷入 "抄袭门" 。 最新消息，OpenAI斥64亿美金收购的AI硬件公司 IO ，因 商标、产品设计侵权 等问题，被告上法庭。 原告是 IYO ，2021年从Google X孵化成立，主营下一代"无屏幕语音计算设备"。 他们表示，OpenAI与LoveFrom团队从2022年开始就多次和IYO接触，包括投资、技术演示、设备试戴等事宜。 但是最终OpenAI拒绝合作，直接推出了IO，定位产品功能几乎一致。 更夸张的是，他们称IO公司共同创始人、工程师甚至曾伪装身份购买IYO产品，也参加了IYO设备佩戴体验。 原告IYO创始人发推：我不会让Sam和Jony偷走我们的名字。 是的，别忘了和奥特曼一起推动IO成立的，还有主导了iPhone、iPad、iMac的 苹果前首席设计师Jony Ive 。前文提到的LoveFrom团队， 就在他名下。 目前最新进展是，OpenAI已经删除了IO相关内容，但AI硬件项目并没有停。 从IYO到…IO？？ 首先来了解下原告IYO。 他们由Google X实验室孵化，2021年正式独立成为 ...

Some of the hottest wheels on the market matched with the best tires on the market.@MartianWheels 🛸 & @MichelinUSA e.Primacy All Season Tries 🛞 https://t.co/Vl7VBMqhEY ...

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association’s (ADA) 85th Scientific ...

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was selected to present new nimacimab data in its expanded preclinical model at the upcoming American Diabetes Association’s (ADA) 85th Scientific Sessions. Skye will present in multiple forums at the ADA conference, which is being held June 20th – 23rd, 2025, ...

Not for distribution to U.S. newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities law. VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (“Marimaca” or the “Company”) (TSX: MARI) (ASX: MC2) is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement (the “Private Placement”) for aggregate gross proceeds of approximate ...

Summary of the Conference Call Company Overview - The conference focused on LENS Therapeutics, discussing their upcoming regulatory update and product launch plans for LENS100, a treatment for presbyopia [1][2]. Regulatory Updates - The PDUFA date for LENS100 is set for August 8, with positive feedback from the FDA during a recent late cycle review [2][4]. - No major or minor observations were noted by the FDA, indicating a smooth regulatory path towards approval [3][4]. Product Differentiation - LENS100 is the only presbyopia treatment utilizing aceclidine, which effectively creates a small pinhole pupil below two millimeters, enhancing near vision without significant side effects [5][6][8]. - In clinical trials, 71% of participants experienced at least three lines of near vision improvement, significantly outperforming competitors like Vuity [10][12]. - The product's efficacy profile shows a sustained effect, with 40% of participants maintaining improvement at ten hours post-application, compared to only 10% for Vuity [10][12]. Market Potential - The presbyopia market is estimated to exceed $3 billion, with 128 million presbyopes in the U.S. and 4 million new cases annually [13][14]. - The company anticipates a 6% penetration rate among presbyopes, leading to approximately 8 million long-term users [16][20]. - The pricing strategy is expected to be around $79 per prescription, similar to Vuity, which had a successful launch with 150,000 scripts sold [19][20]. Commercial Strategy - A sales force of 88 representatives has been established, primarily targeting optometrists, as they account for 80% of script sales in the presbyopia market [22][24]. - The marketing strategy will focus on digital channels, with a budget of $75 to $80 million for direct-to-consumer (DTC) advertising in the first year [39][67]. - The company plans to sample the product heavily to ensure consumer experience and retention, aiming for a higher refill rate than competitors [49][51]. Financial Outlook - LENS Therapeutics is well-funded, with expectations of reaching cash flow positivity by the PDUFA date, bolstered by a strong balance sheet and non-dilutive cash from licensing deals [65][66]. - The projected commercial spend post-launch is approximately $100 million, with a focus on maintaining a lean operational structure [67][68]. Intellectual Property and Supply Chain - The product is protected by a robust IP portfolio, including five years of data exclusivity upon approval and multiple granted patents [61][62]. - The supply chain is designed to be efficient, with API production in the U.S. and fill-finish operations in Germany, ensuring a duty-free status [55][56]. Future Growth and Licensing - The company is exploring opportunities for expansion through mergers and acquisitions, aiming to build a broader portfolio around LENS100 [70][71]. - Licensing agreements are already in place for markets in China and Southeast Asia, with plans to expand into Europe and other regions through partnerships [73][74]. Conclusion - LENS Therapeutics is positioned for a successful product launch with a strong regulatory outlook, differentiated product offering, and a comprehensive commercial strategy aimed at capturing a significant share of the presbyopia market [1][20][70].

知名分析师郭明錤爆料：新设备预计2027年量产；佩戴方式之一是挂脖；比Humane的AI Pin稍大一点 儿，外形和iPod Shuffle一样紧凑优雅；量产之前，设计和规格可能会变化。有摄像头和麦克风，但没 有显示功能。 模型卷得差不多了，AI硬件竞争开启了。Google前脚刚在I/O大会上预告，整合了Gemini AI的Android XR设备即将问世；OpenAI就紧随其后，宣布将以近65亿美元（约合人民币468亿元）的全股权交易方 式，收购一家硬件初创公司IO。 作为OpenAI史上最大的一笔收购，不是芯片不是模型，而是一家成立才一年的AI硬件公司，这是为 啥？ 一、一盘大棋 IO的老板是乔纳森·艾维（Jony Ive）。 你可能没听说过Jony lve，但你一定知道他的产品。作为曾经的苹果首席设计官，Ive设计了iPhone、 iMac、iPad、MacBook Air等作品，背后的故事太多。乔布斯本人甚至曾把Ive称为"精神伙伴"。2019 年，Ive离开苹果创立设计公司LoveFrom，2024年创立了AI硬件初创公司IO，开发下一代AI设备。 这次收购，创始人Ive不归队，以顾问形式合作，但设 ...

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (TSX: MARI) (ASX: MC2) (“Marimaca” or the “Company”) is pleased to announce the results of the votes cast by ballot at its Annual General Meeting of Shareholders held virtually via webcast on Thursday, June 5, 2025 at 10:00 a.m. (local time in Vancouver, British Columbia) (the “Meeting”). All matters submitted to shareholders for approval as set out in the Company’s Notice of Annual General Meeting of Shareholders and Infor ...